Why Moderna Just Rejected Their Own mRNA Vaccine: Shocking Consequences for Global Health!

Last Tuesday, news of the FDA’s refusal to review Moderna’s mRNA-based flu vaccine reverberated throughout a convention center in San Diego, where participants at Phacilitate’s Advanced Therapies Week expressed concern over the implications for life-saving technologies. This latest FDA action comes at a time when advanced therapies are gaining a rapidly expanding global presence, raising questions about the U.S. regulatory landscape.

Roberta Duncan, former chief scientific officer at Arcturus Therapeutics and current board vice-chair of the Alliance for mRNA Medicines (AMM), addressed the crowd, stating, “What we’re seeing in the U.S. are the policy threats that are impacting not only mRNA-enabling technologies, but all the adjacent technologies in advancement as well.” While Duncan clarified that her comments were not strictly about the regulatory space, they resonated deeply given the context of the FDA’s decision.

Duncan emphasized the broader implications of regulatory scrutiny on all scientific advancements, asserting that “any technology where the science is being challenged is a gateway for all technology to be challenged.” She noted that the current “battlefront” is mRNA technology, underscoring the intertwined fate of various innovations.

The mRNA Battlefield

The mRNA technology originally gained prominence through the COVID-19 vaccines developed under Operation Warp Speed during President Donald Trump’s first term. However, since the onset of the second Trump administration, this technology has faced significant threats. In August 2025, the Department of Health and Human Services (HHS) eliminated 22 mRNA programs under the Biomedical Advanced Research and Development Authority, impacting major companies such as Moderna, Pfizer, Sanofi, and AstraZeneca.

Moreover, state-level initiatives are emerging to curb mRNA technology. A proposed bill in South Carolina seeks to prohibit the administration of synthetic mRNA-based products for the prevention of communicable diseases, imposing penalties on healthcare providers who do not comply. The AMM has actively opposed such legislation, as highlighted by Duncan’s statement regarding recent lobbying efforts.

In a statement issued on February 12, AMM Executive Director Clay Alspach criticized the FDA’s refusal-to-file (RTF) letter for Moderna’s mRNA-1010, suggesting it reflects a troubling pattern of regulatory inconsistency. Alspach remarked, “While regulatory scrutiny is vital, decisions that appear to override established review processes undermine confidence in the agency’s work and the innovative treatments and vaccines it ultimately approves.” This sentiment echoes a growing frustration among biotech companies facing conflicting FDA guidance.

The FDA’s refusal to engage with Moderna is indicative of a broader communications crisis affecting multiple companies, including Sarepta, Capricor, and uniQure, over the past nine months. In response to the U.S. government’s adversarial stance toward mRNA technology, Moderna has recently shifted its investment strategy. CEO Stéphane Bancel announced at the World Economic Forum in Davos that the company would no longer pursue late-stage vaccine studies in the U.S. He commented, “You cannot make a return on investment if you don’t have access to the U.S. market.”

While Moderna’s pivot may signal a canary in the coal mine for the biopharma sector, other companies like Pfizer have not yet made significant pipeline changes. Pfizer’s CEO Albert Bourla criticized U.S. Health Secretary Robert F. Kennedy Jr. at the same forum, labeling his views on vaccines as “anti-science.”

Global Regulators on Board

As the U.S. grapples with internal regulatory challenges, the global landscape for advanced therapies is evolving. Duncan articulated the need for a more global approach, stating, “We can no longer treat multinational access as a luxury; it is a requirement.” With increasing uncertainty in the U.S., companies are now prioritizing markets in Europe and Asia-Pacific for diversification purposes. Michael Meyers, head of M&A and Strategic Advisory Services at H.C. Wainwright, stated that companies should consider “lessening country risk and regional risk” in their portfolios.

Currently, Moderna awaits regulatory decisions for mRNA-1010 in Canada, Australia, and Europe, which could potentially lead to availability for the 2027–2028 flu season. The timing for a U.S. market launch remains uncertain. On February 10, Moderna also announced a partnership with Mexico to supply respiratory vaccines and collaborate on local clinical research, with Bancel expressing pride in supporting Mexico’s health initiatives.

Companies like Nanoscope Therapeutics are finding smoother interactions abroad, such as with Japan’s Ministry of Health, Labour and Welfare, which recently provided constructive feedback for regulatory processes. Duncan shared positive experiences with Japan’s Pharmaceuticals and Medical Devices Agency during the approval of a self-amplifying mRNA COVID-19 vaccine, citing continuous engagement that facilitated quicker progress.

In contrast, Biohaven’s CEO Vlad Coric, whose company recently faced an FDA rejection for a rare disease treatment, expressed frustration over the lack of constructive collaboration with the agency. “We have not seen the constructive collaboration with us but we will keep at it,” he stated.

As regulatory landscapes shift, AMM’s Alspach reiterated the potential risks to American biomedical innovation. He warned that “discriminatory decision-making against a proven technology threatens to chill investment, stall innovation, and weaken American leadership in biotechnology.” The questions remain: Is the White House paying attention, and what will be the long-term implications for the U.S. innovation ecosystem?

BioSpace is a media partner of Phacilitate’s Advanced Therapies Week, held February 9–12 at the San Diego Convention Center.